Derivatives of phenylacetic acid. Included under this heading are a variety of acid forms, salts, esters, and amides that contain the benzeneacetic acid structure. Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ACETIC ACID.

A method for analyzing enzyme kinetics with substrate activation and inhibition and its application to the alpha-chymotrypsin-catalyzed hydrolysis of phenyl acetates. (1/729)

A general kinetic method was developed to analyze enzyme-catalyzed systems complicated by the presence of activation or inhibition by substrate. The method was applied to the alpha-chymotrypsin [EC 3.4.21.1]-catalyzed hydrolysis of p-chlorophenyl and p-methoxyphenyl acetates. Deacylation rate constants which were not complicated by substrate activation were obtained. The analysis shows that the abnormal substituent dependence of kcat in the steady state hydrolysis is due not to substrate activation but to inappropriateness of the two-step mechanism or the existence of more than one acetyl-enzyme intermediate.  (+info)

Antagonist activity of alpha-substituted 4-carboxyphenylglycine analogues at group I metabotropic glutamate receptors expressed in CHO cells. (2/729)

1. We have investigated the antagonist properties of 6 alpha-substituted phenylglycine analogues based on the structure of 4-carboxyphenylglycine (4-CPG) for group I metabotropic glutamate receptors (mGlu1alpha and mGlu5a) permanently expressed in CHO cells. 2. (S)-4-CPG and (S)-MCPG were the most selective mGlu1alpha receptor antagonists. Longer chain alpha-carbon substitutions resulted in a progressive loss of antagonist affinity at mGlu1alpha receptors but not at mGlu5a receptors. Thus mGlu1alpha receptor antagonists require small aliphatic groups at the alpha-position. Alpha-cyclopropyl-4-CPG showed a tendency towards mGlu5a selectivity, suggesting that bulky groups at this position may favour mGlu5a receptor antagonism. 3. We demonstrate that the mGlu5a receptor displays agonist-dependent antagonism. L-glutamate-induced Ca2+ release in mGlu5a receptor expressing cells was more susceptible to antagonism by cyclic alpha-carbon derivatives than (S)-3,5-dihydroxyphenylglycine (DHPG)-induced Ca2+ release in the same cell line. 4. The data presented suggests that mGlu1alpha and mGlu5a receptors have different steric and/or conformational requirements for the binding of antagonists and different amino acids which could interact with agonists. 5. These phenylglycine analogues could provide leads for the development of subtype selective antagonists.  (+info)

Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. (3/729)

PURPOSE: To determine the response rate, time to treatment failure, and toxicity of phenylacetate in patients with recurrent malignant glioma and to identify plasma concentrations achieved during repeated continuous infusion of this agent. PATIENTS AND METHODS: Adult patients with recurrent malignant glioma were treated with phenylacetate. The schedule consisted of a 2-week continuous, intravenous infusion followed by a 2-week rest period (14 days on, 14 days off). A starting dose of 400 mg/kg total body weight per day of phenylacetate was initially used and subsequently changed to 400 mg/kg/d based on ideal body weight. Intrapatient dose escalations were allowed to a maximum of 450 mg/kg ideal body weight/d. Tumor response was assessed every 8 weeks. The National Cancer Institute common toxicity criteria were used to assess toxicity. Plasma concentrations achieved during the patients' first two 14-day infusions were assessed. RESULTS: Forty-three patients were enrolled between December 1994 and December 1996. Of these, 40 patients were assessable for toxicity and response to therapy. Reversible symptoms of fatigue and somnolence were the primary toxicities, with only mild hematologic toxicity. Thirty (75%) of the 40 patients failed treatment within 2 months, seven (17.5%) had stable disease, and three (7.5%) had a response defined as more than 50% reduction in the tumor. Median time to treatment failure was 2 months. Thirty-five patients have died, with a median survival of 8 months. Pharmacokinetic data for this dose schedule showed no difference in the mean plasma concentrations of phenylacetate between weeks 1 and 2 or between weeks 5 and 6. CONCLUSION: Phenylacetate has little activity at this dose schedule in patients with recurrent malignant glioma. Further studies with this drug would necessitate an evaluation of a different dose schedule.  (+info)

Spinal reflexes and the concentrations of 5-HIAA, MHPG, and HVA in lumbar cereborspinal fluid after spinal lesions in man. (4/729)

Descending bulbospinal pathways that employ specific neurotransmitter substances are known to be capable of modulating segmental reflex activity in the experimental animal. To determine whether this might also occur in man correlations have been sought between the activity in spinal reflex pathways and the lumbar cerebrospinal fluid (CSF) concentrations of 5-hydroxyindolacetic acid (5-HIAA), 3 methoxy-4-hydroxyphenylglycol (MHPG), and homovanillic acid (HVA) in 12 patients with complete or virtually complete spinal lesions. The concentrations of 5-HIAA and MHPG in lumbar CSF ARE REDUCED AFTER COMPLETE OR VIRTUALLY COMPLETE SPINAL LESIONS IN MAN. This may occur within 18 days of the lesion. MHPG concentrations appear to be inversely related to the level of the lesion. The HVA concentration in lumbar CSF is reduced when there is obstruction of the CSF pathways. No relationship could be demonstrated between the concentrations of 5-HIAA or MHPG in lumbar CSF and the activity in the spinal monosynaptic pathway (estimated from the proportion of the motoneurone pool activated by the Achilles tendon reflex or H reflex) or the activity of a spinal inhibitory mechanism (estimated by the degree of vibratory inhibition of the monosynaptic reflex). Patients with a tonic vibration reflex (TVR) tended to have higher MHPG levels. There appeared to be an association between low CSF HVA and enhanced vibratory inhibition of the monosynaptic reflex in the nine patients whose spinal lesions were complete.  (+info)

Failure to thrive and death in early infancy associated with raised urinary homovanillic and vanillylmandelic acids. (5/729)

A case of failure to thrive in an infant with persistently raised urinary levels of homovanillic and vanillylmandelic acids is descirbed. No neural crest tumour was discovered at surgical exploration or at necropsy. The relation of this biochemical abnormality and failure to thrive is unclear.  (+info)

New methods for determining the enantiomeric purity of erythro -sphingosine. (6/729)

The enantiomeric purity of erythro -sphingosine samples can be determined simply, reliably, and accurately from 1H or 19F nuclear magnetic resonance spectra of the alpha-methoxy-alpha-(trifluoromethyl)phenylacetate (MTPA) derivative. As little as 0.1% of the minor enantiomer could be observed in a 1-mg sample, and detection limits of 1% and 5% were estimated for samples of 100 microg and 10 microg. The two threo -sphingosine enantiomers and four dihydrosphingosine stereoisomers were also differentiated by this technique, which served as an effective method for assessing the purity of sphingosine and dihydrosphingosine samples. Enantiomeric and diastereomeric purities could also be determined by normal-phase high performance liquid chromatographic analysis of the MTPA derivatives.  (+info)

Glutamate receptor expression regulates quantal size and quantal content at the Drosophila neuromuscular junction. (7/729)

At the Drosophila glutamatergic neuromuscular junction, the postsynaptic cell can regulate synaptic strength by both changing its sensitivity to neurotransmitter and generating a retrograde signal that regulates presynaptic transmitter release. To investigate the molecular mechanisms underlying these forms of plasticity, we have undertaken a genetic analysis of two postsynaptic glutamate receptors that are expressed at this synapse. Deletion of both genes results in embryonic lethality that can be rescued by transgenic expression of either receptor. Although these receptors are redundant for viability, they have important differences. By transgenically rescuing the double mutant, we have investigated the relationship of receptor gene dosage and composition to synaptic function. We find that the receptor subunit composition regulates quantal size, Argiotoxin sensitivity, and receptor desensitization kinetics. Finally, we show that the activity of the receptor can regulate the retrograde signal functioning at this synapse. Thus, the diversity of receptors expressed at this synapse provides the cell with mechanisms for generating synaptic plasticity.  (+info)

Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. (8/729)

ZD7114, [(S)-4-[2-(2-hydroxy-3 phenoxypropylamine)ethoxy]-N-(2-methoxyethyl) phenoxyacetamide], and ZD2079, [(R)-N-(2-[4- (carboxymethyl)phenoxy]ethyl)-N-(beta-hydroxyphenethyl)ammonium chloride], are beta 3-adrenoceptor stimulants with selectivity for brown adipose tissue. ZD7144 is the hydrochloride salt of the S-enantiomer of the racemic amide ZD2079. They were developed as potential novel treatments for obesity and non-insulin-dependent diabetes mellitus. Male and female rats were dosed separately by gavage for a minimum of 28 days with 0, 10, 50, and 500 mg/kg/day of ZD7114 or with 0, 10, 30, and 150 mg/kg/day of ZD2079. Two further groups of male and female rats were dosed with 0 and 500 mg/kg/day of ZD7114 for 28 days and were then allowed a 6-wk, undosed withdrawal period. At high doses, both compounds caused urinary tract toxicity, which primarily affected the distal tubules and collecting ducts of the kidney via tubular necrosis. They also caused ureteric inflammation, cystitis, and accumulation of crystalline inclusions throughout the urinary tract. As a result of urinary tract toxicity, affected animals from one or both studies showed reduced red blood cell indices, lower platelet counts, and higher white cell counts. Blood chemistry revealed lower plasma concentrations of glucose (7.28 +/- 1.37 compared to 8.11 +/- 0.65 for the control) and total protein (63.42 +/- 3.65 compared to 69.17 +/- 3.24 for the control) and increased plasma urea (37.15 +/- 19.96 compared to 8.09 +/- 0.87 for the control). Urinalysis showed an increase in the number of crystals, blood, and protein. In the urinary tract, the severe crystalluria with accumulation of crystalline material indicated that this may have a role in the etiology of the target organ toxicity. Poor solubility of the compounds at normal urinary pH was considered a possible mechanism for the crystalluria.  (+info)

Phenylacetates are a group of organic compounds that contain a phenyl group (a benzene ring with a hydroxyl group) and an acetic acid group. In the context of medicine, sodium phenylacetate is used in the treatment of certain metabolic disorders, such as urea cycle disorders, to help remove excess ammonia from the body. It does this by conjugating with glycine to form phenylacetylglutamine, which can then be excreted in the urine.

It is important to note that the use of phenylacetates should be under the supervision of a medical professional, as improper use or dosage can lead to serious side effects.

... may refer to: Phenyl acetate, the ester of phenol and acetic acid The conjugate base of phenylacetic acid This ...
... has a strong odor similar to honey. This compound also occurs in brandy, capsicum, coffee, honey, pepper, ... Methyl phenylacetate is an organic compound that is the methyl ester of phenylacetic acid, with the structural formula ... ISBN 9780470842898.{{cite journal}}: CS1 maint: multiple names: authors list (link) "Methyl Phenyl Acetate."(February 22, 2007 ... Methyl phenyldiazoacetate, precursor to cyclopropanation agents, is prepared by treating methyl phenylacetate with p- ...
... can be separated into phenol and an acetate salt, via saponification: heating the phenyl acetate with a strong ... Phenyl acetate is the ester of phenol and acetic acid. It can be produced by reacting phenol (Which can be produced by ... Phenyl acetate, Alfa Aesar Seo, Sangwon; Taylor, John B.; Greaney, Michael F. (2012-07-23). "Protodecarboxylation of benzoic ...
... is one of only a few known ligands for the human olfactory receptor OR51L1. "Allyl phenyl acetate". The ... Allyl phenylacetate is an ester with a fruity honey odor, used in the perfume and flavoring industries. It is the ester ... George A. Burdock (2010), "Allyl Phenylacetate", Fenaroli's Handbook of Flavor Ingredients (6th ed.), Taylor & Francis, p. 65 ( ...
... (Perandren Phenyl- acetate®): This microcrystalline aqueous suspension for intramuscular use has a ... Testosterone phenylacetate (Perandren phenylacetate)-Long-acting suspension of macrocrystals. Dose, 100 to 200 mg. ... and 354 mg testosterone phenylacetate in aqueous suspension had a duration of 66 days. In 1955, testosterone phenylacetate in ... Testosterone phenylacetate was a 50 mg/mL microcrystalline aqueous suspension under the brand name Perandren. It was used at a ...
In enzymology, a phenylacetate-CoA ligase is an enzyme (EC 6.2.1.30) that catalyzes the chemical reaction ATP + phenylacetate ... The systematic name of this enzyme class is phenylacetate:CoA ligase (AMP-forming). Other names in common use include ... phenylacetate, and CoA. Its 3 products are AMP, diphosphate, and phenylacetyl-CoA. This enzyme belongs to the family of ligases ...
Adams, Roger; Thal, A. F. (1922). "Ethyl Phenylacetate". Organic Syntheses. 2: 27. doi:10.15227/orgsyn.002.0027. Elvidge, J. A ...
Adams, Roger; Thal, A. F. (1922). "Ethyl Phenylacetate". Organic Syntheses. 2: 27. doi:10.15227/orgsyn.002.0027. Robinson, John ...
Adams R, Thal AF (1922). "Ethyl Phenylacetate". Organic Syntheses. 2: 27. doi:10.15227/orgsyn.002.0027. Meyer GM, Levene PA ( ...
Phenylacetate catabolism in Escherichia coli". European Journal of Biochemistry. 270 (14): 3047-54. doi:10.1046/j.1432- ... "Bacterial phenylalanine and phenylacetate catabolic pathway revealed". Proceedings of the National Academy of Sciences of the ...
Phenylacetate catabolism in Escherichia coli". European Journal of Biochemistry. 270 (14): 3047-54. doi:10.1046/j.1432- ... "Bacterial phenylalanine and phenylacetate catabolic pathway revealed". Proceedings of the National Academy of Sciences of the ...
Phenylacetate catabolism in Escherichia coli". European Journal of Biochemistry. 270 (14): 3047-54. doi:10.1046/j.1432- ... "Bacterial phenylalanine and phenylacetate catabolic pathway revealed". Proceedings of the National Academy of Sciences of the ...
Asakawa T, Wada H, Yamano T (1968). "Enzymatic conversion of phenylpyruvate to phenylacetate". Biochim. Biophys. Acta. 170 (2 ...
Metabolites include phenylacetate, phenylpyruvate and phenethylamine. Elevated levels of phenylalanine in the blood and ... due to phenylacetate, a carboxylic acid produced by the oxidation of phenylacetone). In most cases, a repeat test should be ...
"Bacterial phenylalanine and phenylacetate catabolic pathway revealed". Proceedings of the National Academy of Sciences of the ... 2-epoxidase participates in catabolism of phenylacetate in Escherichia coli and Pseudomonas putida. Teufel R, Mascaraque V, ...
Hyperammonemia is treated with hemodialysis; intravenous arginine, sodium benzoate, and sodium phenylacetate. In some cases, ...
It is a diazo derivative of methyl phenylacetate. Colloguially referred to as "phenyldiazoacetate", it is generated and used in ... Methyl phenyldiazoacetate is prepared by treating methyl phenylacetate with p-acetamidobenzenesulfonyl azide in the presence of ...
Cathinone Methyl phenylacetate Haynes, William M., ed. (2016). CRC Handbook of Chemistry and Physics (97th ed.). CRC Press. pp ... The sodium salt of phenylacetic acid, sodium phenylacetate, is used as a pharmaceutical drug for the treatment of urea cycle ... Phenylacetic acid (conjugate base phenylacetate), also known by various synonyms, is an organic compound containing a phenyl ... 4, p. 760 "Sodium Phenylacetate and Sodium Benzoate Monograph for Professionals". Drugs.com. Retrieved 16 November 2019. (CS1 ...
Arginine is usually administered with benzoate and phenylacetate. This is best administered in the setting of a major medical ... Glycerol phenylbutyrate is a pre-prodrug that undergoes metabolism to form phenylacetate. Results of a phase 3 study comparing ... Intravenous sodium benzoate and sodium phenylacetate may be helpful. ... evenly distributed urinary output of PAGN over 24 hours and accounted for fewer symptoms from accumulation of phenylacetate. In ...
... is an ultra short-acting phenylacetate general anesthetic. It was originally introduced by Bayer in 1963 but ...
Jencks, William P.; Carriuolo, Joan (February 1960). "General Base Catalysis of the Aminolysis of Phenyl Acetate". Journal of ...
This enzyme was also incubated with phenylacetate and p-hydroxyphenylacetate and there was no activity, indicating high ... These bacteria create indoleacetate, p-hydroxyphenylacetate and phenylacetate, respectively. In addition, some bacteria carry ...
... phenylacetate. Phenylacetate conjugates with glutamine to phenylacetylglutamine, which is eliminated with the urine. It ... Use of sodium phenylbutyrate was introduced in the early 1990s, as it lacks the odor of phenylacetate. In cystic fibrosis, a ... It is metabolized into phenylacetate within half an hour. "Prescription medicines: registration of new chemical entities in ... Another 1919 article had used sodium phenylacetate, and so the researchers treated 5 patients with hyperammonemia with benzoate ...
William P. Jencks; Joan Carriuolo (1960). "General Base Catalysis of the Aminolysis of Phenyl Acetate". Journal of the American ...
ATP + phenylacetate + CoA → AMP + diphosphate + phenylacetyl-CoA This reaction is catalyzed by phenylacetate-CoA ligase. ... It is formed via the actions of Phenylacetate-CoA ligase. Phenylacetyl-CoA is often produced via the reduction of ATP to AMP ... and the conversion of phenylacetate and CoA to diphosphate and Phenylacetyl-CoA. ...
Glycerol phenylbutyrate Sodium phenylacetate Sodium phenylbutyrate Jiang Y, Almannai M, Sutton VR, Sun Q, Elsea SH (November ... Phenylbutyrate is beta-oxidized into phenylacetate which is conjugated with glutamine in the liver and excreted by the kidney. ... The metabolism and conjugation of phenylacetate with glutamine in the liver involves amino acid acetylation carried out by the ... Phenylacetylglutamine is a product formed by the conjugation of phenylacetate and glutamine. It is a common metabolite that ...
Substituted acetophenones can be converted to the corresponding phenyl acetates at 30 °C in high yields. The rate is about 100 ...
Arginine, sodium benzoate and sodium phenylacetate help to remove ammonia from the blood. Dialysis may be used to remove ...
Hocking, M.B. (1980). "Phenyl acetate preparation from phenol and acetic acid: Reassessment of a common textbook misconception ...
... production starts with a based catalyzed condensation between phenyl acetate and acid chloride. To form the ring of ...
Phenylacetate may refer to: Phenyl acetate, the ester of phenol and acetic acid The conjugate base of phenylacetic acid This ...
... Molecular Formula: C17H14O5 ...
Learn about the side effects of sodium benzoate/sodium phenylacetate, from common to rare, for consumers and healthcare ... Some side effects of sodium benzoate / sodium phenylacetate may occur that usually do not need medical attention. These side ... Sodium benzoate / sodium phenylacetate Side Effects. Medically reviewed by Drugs.com. Last updated on Jan 27, 2023. ... Applies to sodium benzoate / sodium phenylacetate: intravenous solution.. General. -The most frequently reported adverse ...
Isoamyl phenylacetate, a phenethyl alcohol derivative,. is commonly used as a flavor additive in tobacco.. It is one of the ... 3-methylbutyl 2-phenylacetate, Iso amyl alpha-toluate, Phenyl acetic acid isopentyl ester ...
Suitable products for Phenyl acetate C8H8O2. Whether portable gas detectors, gas detection tubes or personal protective ...
However, during the fermentation process, phenylacetate can be produced from phenylalanine. As phenylacetate inhibits bacterial ... Aside from phenylacetate, chloride, nitrate, sulfite, sulfate, phosphate, and thiosulfate are also determined in the ... However, during the fermentation process, phenylacetate can be produced from phenylalanine. As phenylacetate inhibits bacterial ... Aside from phenylacetate, chloride, nitrate, sulfite, sulfate, phosphate, and thiosulfate are also determined in the ...
4-[(Phenylcarbamoyl)sulfanyl]phenyl acetate | C15H13NO3S | CID 71388168 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
2-amino-2-phenylacetate , C12H15NO2 , CID 61151251 - structure, chemical names, physical and chemical properties, ...
"Phenylacetates" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject ... Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ... This graph shows the total number of publications written about "Phenylacetates" by people in this website by year, and whether ... Below are the most recent publications written about "Phenylacetates" by people in Profiles. ...
We have demonstrated that phenylacetate(PA)-induced cell cycle arrest in human prostate cancer is mediated by increase of p27. ... Down-regulation of Skp2 is Correlated with p27-associated Cell Cycle Arrest Induced by Phenylacetate in Human Prostate Cancer ... Down-regulation of Skp2 is Correlated with p27-associated Cell Cycle Arrest Induced by Phenylacetate in Human Prostate Cancer ... Down-regulation of Skp2 is Correlated with p27-associated Cell Cycle Arrest Induced by Phenylacetate in Human Prostate Cancer ...
3958PHENYL ACETATE search Extended Navigation. Main Menu. * About back About. *About ...
... guanidinium cation gives three cyclic hydrogen-bonding interactions with O-atom acceptors of three independent phenylacetate ...
Putative Phenylacetate-CoA ligase. Bradyrhizobium sp. ORS 285. Putative phenylacetate--coenzyme A ligase. Methanocella ... Phenylacetate metabolism in thermophiles: characterization of phenylacetate-CoA ligase, the initial enzyme of the hybrid ... Characterization of a phenylacetate-CoA ligase from Penicillium chrysogenum. * Metabolic handoffs between multiple symbionts ... Phenylacetate-coenzyme A ligase. Escherichia coli (strain K12). ...
Disclaimer - The information contained in ACS International product documentation is believed to be accurate to the best of our knowledge. ACS International reserves the right to discontinue or add ingredients to its portfolio or change product specifications without prior notice ...
... phenylacetate. Pomáháme vědě tím, že nabízíme široký výběr produktů, služeb a znalostí našich lidí. ...
We believe the above information to be correct but we do not present it as all inclusive and as such should be used as a guide. PRODASYNTH shall not be held responsible for any damage or injury resulting from contact with the above ...
ETHYL PHENYL ACETATE, Natural (Manufacturing) - Food and Drug Guarantee ETHYL PHENYL ACETATE, Natural (Manufacturing) - Food ... ETHYL PHENYL ACETATE, Natural (Manufacturing) - Certificate of Origin ETHYL PHENYL ACETATE, Natural (Manufacturing) - Country ... ETHYL PHENYL ACETATE, Natural (Manufacturing) - Food Grade Certification ETHYL PHENYL ACETATE, Natural (Manufacturing) - Food ... ETHYL PHENYL ACETATE, Natural (Manufacturing) - GMO Declaration ETHYL PHENYL ACETATE, Natural (Manufacturing) - Gluten Free ...
Geranyl Phenyl Acetate. Geranyl Phenyl Acetate Supplier, Geranyl Phenyl Acetate Distributor, Geranyl Phenyl Acetate ... Refractive Index of Geranyl Phenyl Acetate. 1.5060 - 1.5110 @ 20C Specific Gravity of Geranyl Phenyl Acetate. 0.9710 - 0.9780 ... Manufacturer, Geranyl Phenyl Acetate Essential Oils, Aromatic Chemicals. +1 973 748 8980 • 700 Blair Road, Carteret, NJ 07008 ...
101-97-3,Ethyl phenylacetate, 99%,MFCD00009178,Benzeneaciticacidethylester
Learn more about Ethyl {4-[(chloroacetyl)amino]phenyl}acetate. We enable science by offering product choice, services, process excellence and our people make it happen.
Phenyl acetate. Catalog No.:. 682794. Relevant identified uses of the substance or mixture. Identified: Laboratory chemical. ...
We can supply Methyl phenylacetate for you. Nordmann sources the highest quality raw materials from leading manufacturers and ...
ethyl 2-(3-hydroxy-4-methoxy-phenyl)acetate. CAS Registry Number:. 20044-87-5. Synonyms:. Molecular Formula:. C11H14O4. ... The Complete List of Suppliers for ethyl 2-(3-hydroxy-4-methoxy-phenyl)acetate ...
For more information, please view Spec of ethyl 2-(4-(aminomethyl)phenyl)acetate 62910-48-9.pdf. ...
A gravimetric technique to evaluate brain oedema in pigs with acute liver failure : effect of L-Ornithine Phenylacetate ... L-ornithine phenylacetate (OP). Methods: 24 Norwegian Landrace pigs were used in this study. ALF was induced by hepatic ...
Saleem, R., Shabir, G., Hanif, M., Qadeer, G., & WONG, W. Y. (2008). Methyl 2-[2-(2,6-dichloro-anilino)-phenyl]-acetate. Acta ... Saleem, R, Shabir, G, Hanif, M, Qadeer, G & WONG, WY 2008, Methyl 2-[2-(2,6-dichloro-anilino)-phenyl]-acetate, Acta ... Methyl 2-[2-(2,6-dichloro-anilino)-phenyl]-acetate. Rashid Saleem, Ghulam Shabir, Muhammad Hanif, Ghulam Qadeer*, Wai Yeung ... Methyl 2-[2-(2,6-dichloro-anilino)-phenyl]-acetate. In: Acta Crystallographica Section E: Structure Reports Online. 2008 ; Vol ...
4-(3-Oxobutyl)phenyl acetate CAS 56218-81-6 2021年1月12日. /in Pheromones /by great_watson-int. Name. 4-(3-Oxobutyl)phenyl acetate ... You are here: Home1 / Pheromones2 / 4-(3-Oxobutyl)phenyl acetate CAS 56218-81-6 ...
Product Name: 3-(4-Oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate. Synonyms: 3-(4-Oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate; ... 3-(4-Oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate Usage And Synthesis. 3-(4-Oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate ... Please use the form above to make an enquiry about 3-(4-Oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate CAS no 37 remembering to ... 3-(4-Oxo-3,4-dihydroquinazolin-2-yl)phenyl acetate CAS no 371947-93-2 4(1H)-Quinazolinone, 2-[3-(acetyloxy)phenyl]-. 4(1H)- ...
  • These highlights do not include all the information needed to use SODIUM PHENYLACETATE AND SODIUM BENZOATE INJECTION safely and effectively. (nih.gov)
  • Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in pediatric and adult patients with deficiencies in enzymes of the urea cycle. (nih.gov)
  • Sodium Phenylacetate and Sodium Benzoate Injection must be diluted with sterile 10% Dextrose Injection (D10W) before administration. (nih.gov)
  • Sodium Phenylacetate and Sodium Benzoate Injection is administered intravenously as a loading dose infusion administered over 90 to 120 minutes, followed by an equivalent maintenance dose infusion administered over 24 hours. (nih.gov)
  • Injection: 10% per 10% sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. (nih.gov)
  • Sodium Phenylacetate and Sodium Benzoate Injection contains 30.5 mg of sodium per mL of undiluted product. (nih.gov)
  • Caution should be used if Sodium Phenylacetate and Sodium Benzoate Injection is administered to patients with congestive heart failure, severe renal insufficiency, or with conditions in which there is sodium retention with edema. (nih.gov)
  • Extravasation of Sodium Phenylacetate and Sodium Benzoate Injection into the perivenous tissues during high flow bolus infusion may lead to skin necrosis, especially in infants. (nih.gov)
  • Sodium Phenylacetate and Sodium Benzoate Injection may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. (nih.gov)
  • Valproic acid given to patients with urea cycle disorders may exacerbate their condition and antagonize the efficacy of Sodium Phenylacetate and Sodium Benzoate Injection through inhibition of the synthesis of N-acetylglutamate, a co-factor for carbamyl phosphate synthetase. (nih.gov)
  • The combination of intravenous sodium phenylacetate and sodium benzoate has been shown to lower plasma ammonium levels and improve survival in small cohorts of patients with historically lethal urea-cycle enzyme defects. (nih.gov)
  • We report the results of a 25-year, open-label, uncontrolled study of sodium phenylacetate and sodium benzoate therapy (Ammonul, Ucyclyd Pharma) in 299 patients with urea-cycle disorders in whom there were 1181 episodes of acute hyperammonemia. (nih.gov)
  • valproic acid decreases effects of sodium phenylacetate by pharmacodynamic antagonism. (medscape.com)
  • amoxicillin, sodium phenylacetate. (medscape.com)
  • ampicillin, sodium phenylacetate. (medscape.com)
  • nafcillin, sodium phenylacetate. (medscape.com)
  • penicillin G aqueous, sodium phenylacetate. (medscape.com)
  • penicillin VK, sodium phenylacetate. (medscape.com)
  • pivmecillinam, sodium phenylacetate. (medscape.com)
  • probenecid increases levels of sodium phenylacetate by decreasing renal clearance. (medscape.com)
  • temocillin, sodium phenylacetate. (medscape.com)
  • ticarcillin, sodium phenylacetate. (medscape.com)
  • Monitor Closely (1) amoxicillin, sodium phenylacetate. (medscape.com)
  • Monitor Closely (1) penicillin G aqueous, sodium phenylacetate. (medscape.com)
  • Intravenous sodium benzoate and sodium phenylacetate have been used successfully in the treatment of acute hyperammonaemia in patients with urea cycle disorders. (nih.gov)
  • However, we report three patients with hyperammonaemia who received inappropriate doses of intravenous sodium benzoate and sodium phenylacetate that resulted in severe complications. (nih.gov)
  • Hyperammonemia treatment consists of sodium benzoate/sodium phenylacetate IV. (medscape.com)
  • For highly elevated ammonia levels, hemodialysis may be the appropriate initial treatment if it is readily available, and it is also recommended for patients whose condition fails to respond to initial course of sodium benzoate/sodium phenylacetate. (medscape.com)
  • Continuing the administration of sodium benzoate/sodium phenylacetate during hemodialysis may be considered. (medscape.com)
  • Sodium benzoate/sodium phenylacetate (Ammonul) is approved by the US Food and Drug Administration (FDA) for treatment of hyperammonemia caused by urea-cycle defects. (medscape.com)
  • Sodium benzoate/sodium phenylacetate may be effective for treatment of hyperammonemia, though hemodialysis is preferred for ammonia levels higher than 500-600 µg/dL. (medscape.com)
  • The preparation contains 100 mg/mL each of sodium phenylacetate and sodium benzoate and is supplied as 50-mL vials. (medscape.com)
  • Sodium benzoate/sodium phenylacetate should not be directly mixed with other medications but may be piggybacked. (medscape.com)
  • Off-label use of ondansetron may be considered to control nausea and vomiting associated with Reye syndrome and with IV administration of sodium benzoate/sodium phenylacetate. (medscape.com)
  • Appearance of Sodium phenylacetate was observed. (europa.eu)
  • The chemical Sodium phenylacetate was observed to be an organic compound with the nature white to yellowish colored solid crystalline powder and odorless. (europa.eu)
  • An overview of Genetic Toxicology Bacterial Mutagenicity study conclusions related to Benzyl phenylacetate (102-16-9). (nih.gov)
  • Genetic Toxicity Evaluation of Benzyl Phenylacetate in Salmonella/E.coli Mutagenicity Test or Ames Test. (nih.gov)
  • Phenylacetate degradation.Individual genes re-named paa. (yale.edu)
  • 2019. Molecular basis for metabolite channeling in a ring opening enzyme of the phenylacetate degradation pathway. . (ncbs.res.in)
  • An integrative multiomics approach in nondiabetic obese women identifies phenylacetate as a microbial metabolite contributing to the accumulation of lipids in the liver and hence to nonalcoholic steatohepatitis. (nature.com)
  • This study shows the optimized expression and purification protocols for the decarboxylase and the co-crystallization experiments and binding studies with 4-hydroxy-phenylacetate and 3,4-dihydroxyphenylacetate and with the inhibitor 4-hydroxy-phenylacetamide. (hu-berlin.de)
  • Phenylacetate conjugates (by acetylation) with glutamine in the liver and kidneys to form phenylacetylglutamine (which is excreted by the kidneys). (medscape.com)
  • Evaluating the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury (STOP-ALF) We expect to enroll 6 patients in this part of the project. (northwestern.edu)
  • In terms of clinical trials, the ALFSG currently has ongoing the "A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (ornithine phenylacetate) in the Treatment of Patients with Acute Liver Failure/Severe Acute Liver Injury due to Acetaminophen Overdose" (STOP-ALF). (nih.gov)
  • Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses should not be administered. (nih.gov)
  • Plasma levels of benzoate and phenylacetate were excessively high. (nih.gov)
  • Phenylacetate may refer to: Phenyl acetate, the ester of phenol and acetic acid The conjugate base of phenylacetic acid This set index article lists chemical compounds articles associated with the same name. (wikipedia.org)
  • Additionally, neurotoxicity related to phenylacetate has been reported in cancer patients. (nih.gov)